Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PRA023 in healthy volunteers
NCT04676178Phase 1Completed
- Sponsor
- Prometheus Biosciences
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tulisokibart in ulcerative colitis (UC), Crohn's disease and systemic sclerosis-associated interstitial lung disease (SSc-ILD) (4 arms), sponsored by Prometheus Biosciences. Primary endpoint: Treatment emergent adverse events up to 22 weeks. Started Dec 2020; status: completed.
02
Drugs
tulisokibart
03
Conditions
ulcerative colitis (UC)Crohn's diseasesystemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT04676178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676178.